Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research from S.R.D. Johnston and co-researchers in the area of breast cancer described
July 24th, 2008
According to recent research from London, the United Kingdom, " This study assessed the clinical efficacy of the farnesyltransferase inhibitor, tipifarnib, combined with letrozole in patients with advanced breast cancer and disease progression following antiestrogen therapy. Patients and methods Postmenopausal women with estrogen-receptor-positive advanced breast cancer that had progressed after tamoxifen were given 2.5 mg letrozole once daily and were randomly assigned (2:1) to tipifarnib 300 mg (TL) or placebo (L) twice daily for 21 consecutive days in 28-day cycles." "The primary endpoint was objective response rate. Of 120 patients treated with TL (n = 80) or L (n...
Source: Women's Health Weekly (2008-07-24)
|
